Chair - Professor Małgorzata Kajta (Poland )
Cordian Beyer (Institute of Neuroanatomy, Uniklinik - RWTH Aachen, Aachen – Germany )
Estrogen and brain inflammation.
Elżbieta Salińska (Department of Neurochemistry, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland )
Hyperbaric and hypobaric treatment prevent radical oxygen species (ROS) toxicity in birth asphyxia.
Magdalena Zielińska (Department of Neurotoxicology, Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland )
Astrocytic SN1 glutamine transporter in hyperammonemic encephalopathies.
Małgorzata Kajta (Department of Experimental Neuroendocrinology, Institute of Pharmacology Polish Academy of Sciences, Krakow, Poland )
Steroid and xenobiotic receptor signaling in pathologies of the nervous system.
Chairs - Professor Joanna Pera (Poland ), Profesor Jolanta Sykut-Cegielska (Poland )
Zbigniew A. Gaciong (Department of Internal Medicine, Hypertension and Vascular Diseases, Medical University of Warsaw, Warsaw, Poland )
What can we offer patients with rare vascular diseases?
Jolanta Sykut-Cegielska (Mossakowski Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland )
Inborn errors of metabolism as rare diseases.
Tomasz Dziedzic (Department of Neurology, Jagiellonian University Medical College, Kraków, Poland )
Autoimmune encephalopathies: rare, but treatable neurological disorders.
Joanna Pera (Department of Neurology, Jagiellonian University Medical College, Kraków, Poland )
Adrenoleukodystrophy - beyond fatty acids.
Csaba Földy - Brain Research Institute, University of Zurich, Switzerland
Single-cell transcriptomic survey of neural identity and circuit connectivity
Chairs - Professor Krystyna Gołembiowska (Poland ), Professor Liana Fattore (Italy )
Dariusz Zuba (Institute of Forensic Research, Kraków, Poland )
Recent developments in the new psychoactive substances market.
Linda Simmler (Department of Basic Neurosciences, University of Geneva, Switzerland )
Pharmacology of cathinones and related psychostimulants.
Rosario Moratalla (Cajal Institute (CSIC), Madrid, Spain )
Is methamphetamine abuse a risk factor for Parkinson’s disease?
Liana Fattore (Institute of Neuroscience-Cagliari, National Research Council of Italy, Cittadella Universitaria di Monserrato, Monserrato, Italy )
Studies on the ketamine-like compound metoxetamine (MXE), a dissociative new drug.
Chair - Doctor Katarzyna Kuter (Poland )
M. Angela Cenci (Basal Ganglia Pathophysiology Unit, Dept. of Experimental Medical Science, Lund University, Sweden )
Bridging the translational gap in Parkinson’s disease: challenges and opportunities.
Katarzyna Kuter (Department of Neuropsychopharmacology, Institute of Pharmacology PAS, Kraków, Poland )
Astrocytes and brain compensation potential in Parkinson’s disease.
Bianca Marchetti (Department of Biomedical and Biotechnological Sciences, University of Catania Medical School, Catania, Italy & and OASI Institute for Research and Care on Mental Retardation and Brain Aging, Troina, Italy )
Translating neurorestorative approaches targeting astrocytes as drivers of neurorepair for next generation therapies in Parkinson’s disease.
Chairs - Professor Jan Rodriguez Parkitna (Poland )
János Szabadics (Institute of Experimental Medicine, Hungarian Academy of Sciences, Budapest, Hungary )
Chair - Professor Agnieszka Dobrzyń (Poland )
Harini Sampath (Rutgers Center for Lipid Research, Rutgers University, NJ, USA )
Oxidative DNA damage: a novel player in the etiology of obesity.
Grzegorz Sumara (Rudolf Virchow Center for Experimental Biomedicine University of Würzburg, Würzburg, Germany )
Agnieszka Dobrzyń (Nencki Institute of Eperimental Biology, PAS, Warsaw, Poland )
Lipid mediators in regulation of pancreatic islet function.
Chairs - Professor W. Anna Daniel (Poland ), Professor Julia Stingl (Germany )
Władysława Anna Daniel (Institute of Pharmacology, PAS, Kraków, Poland )
Introduction into pharmacogenetics.
Julia Stingl (Centre for Translational Medicine, Medical Faculty, University Bonn, Germany )
Mindful pharmacogenetics: the role of cytochrome P450 enzymes in drug metabolism and mental health.
Mateusz Kurzawski (Department of Experimental and Clinical Pharmacology, Pomeranian Medical University, Szczecin, Poland )
Genetic factors and personalized medicine in Parkinson's disease.
Ewa Grzybowska (Center for Translational Research and Molecular Biology of Cancer, Maria Skłodowska-Curie Memorial Cancer Center and Institute of Oncology, Gliwice, Poland )
Modulation of response to treatment and toxic effects of FAC regimen chemotherapy of breast cancer by genetic variants of ADME genes.
Ewa Wypasek (John Paul II Hospital, Institute of Cardiology, Jagiellonian University School of Medicine, Kraków, Poland, Kraków, Poland )
Genetic predictors of bleeding in patients treated with vitamin K antagonists: new insight.
Ulrik Gether - University of Copenhagen, Denmark
The dopamine transporter: a key player in psychostimulant addiction and dopaminergic pathologies
Chair - Professor Ireneusz Grudziński (Poland )
Witold Łojkowski (Institute of High Pressure Physics of the Polish Academy of Sciences, Warsaw, Poland )
Hydroxyapatite nanoparticles: Past, present, and future in bone regeneration.
Tomasz Ciach (Warsaw University of Technology, Warsaw, Poland )
Cancer nanotechnology: Beyond the horizon.
Leszek Stobiński (Warsaw University of Technology, Warsaw, Poland )
Carbon nanoparticles for future nanomedicine.
Marcin Kruszewski (Institute of Nuclear Chemistry and Technology, Warsaw, Poland )
New look into theranostic nanoparticles in nuclear medicine.
Anna Nowicka (University of Warsaw, Warsaw, Poland )
Nanosensors in POC diagnostics.
Chairs - Professor Tomasz Kocki (Poland ), Professor Magdalena Bujalska-Zadrożny (Poland )
Camila V. Esguerra (Group Leader, Chemical Neuroscience Group Center for Molecular Medicine Norway Associate Professor, School of Pharmacy University of Oslo, Norway )
Using zebrafish to model genetic epilepsies and elucidate drug mechanism of action.
Rafał Kamiński (Experimental Therapeutics at UCB, UCB Université Libre de Bruxelles, Brussels Area, Belgium )
Novel approaches to discovery of future antiepileptic drug targets.
Urszula Doboszewska (Department of Animal Physiology, Institute of Biology and Biochemistry, Faculty of Biology and Biotechnology, Maria Curie-Skłodowska University, Lublin, Poland )
The role of the GPR39 receptor in animal models of seizures and epilepsy.
Piotr Maciejak (Department of Neurochemistry, Institute of Psychiatry and Neurology, Warsaw, Poland; Department of Experimental and Clinical Pharmacology, Medical University of Warsaw, Centre for Preclinical Research and Technology (CePT), Warsaw, Poland )
Neurobiochemical mechanisms of a ketogenic diet: simple rules for a complex reality?
ThermoFisher Scientific, Merck
Workshop topics will be presented on website at July 16, 2018.
Due to the limited availability of seats, registration is strongly recommended and will be provided until August 31, 2018.
Venue: Polish Aviation Museum
Chair - Professor Andrzej Pilc (Poland )
Branden Stansley (Vanderbilt Center for Neuroscience Drug Discovery, Vanderbilt University, USA )
Enhancing mGlu5 signaling for the treatment of cognitive impairment associated with schizophrenia: importance of signal bias and crosstalk with mGlu3.
Andrzej Pilc (Institute of Pharmacology PAS, Poland )
Allosteric mGlu4 receptor modulators as antipsychotic-like drugs a crosstalk with 5HT1A receptors.
Marta Dziedzicka-Wasylewska (Institute of Pharmacology PAS, Poland )
Importance of GPCRs heteromerization in the central nervous system - dopamine receptors as an example.
Chairs - Professor Magdalena Bujalska-Zadrożny (Poland ), Professor Tomasz Kocki (Poland )
Konrad Korbiński (CEO Synergia sp. z o.o., Warsaw Medical University )
Productive and Safe Cooperation Between Scientists and Pharma Industry - safeguarding intellectual property and confidentiality.
Marcin Szczeciński (MBA, Investment Manager, Adamed Sp. z o.o. )
Aspects to consider before launching and early on in a drug discovery program – pharmaceutical industry perspective.
Magdalena Bujalska-Zadrożny (Head of Pharmacodynamic Department, Warsaw Medical University )
From Basic research to medicinal product approval – a brief history of a novel formulation development.
Louis Boon (CSO, Managing Director, Bioceros, a member of Polpharma Biologics )
Discovery, preclinical development and production of therapeutic antibodies.
Bartłomiej Żerek (Head of Drug Discovery Department, Adamed Sp. z o.o. )
Discovery and preclinical evaluation of AD-O21.32, a selective MDM2-p53 protein-protein interaction inhibitor – lessons learned. Andrzej Kuśmierz (Founder of WAW.AC – Warsaw Technology Accelerator )
Breaking ice between industry and academia.
Francesco Pavone - European Laboratory for Non Linear Spectroscopy and Department of Physics, University of Florence, Italy
Morpho-functional imaging: connecting a single neuron to whole brain.
Chairs - Professor Dariusz Zuba (Poland ), Professor Marzena Maćkowiak (Poland )
Chairs - Professor Małgorzata Filip (Poland ), Professor Joanna Pera (Poland )